Zepbound (Tirzepatide)

Name: Zepbound (Tirzepatide)
SKU: 9811
Availability: InStock

From: $199.00

Zepbound (pronounced ZEHP-bownd) is a recently FDA-approved prescription medication containing the active agent tirzepatide. It is designed for chronic weight management in adults with obesity or overweight plus weight-related conditions. Zepbound works alongside lifestyle modifications (diet, exercise) to help reduce excess body weight, and is also approved to help with moderate-to-severe obstructive sleep apnea (OSA) in people with obesity.

Dosage

2.5mg
5mg
10mg
12.5mg
15mg

Clear

Quantity:

Compare

Add to wishlist

SKU: N/A Categories: Diabetes, Fitness, Health Conditions, Treatments, Weight Loss

Description

Mechanism of Action Zepbound (Tirzepatide):
1. Reduces appetite — makes you feel full sooner.
2. Slows gastric emptying — food stays longer in stomach, increasing satiety.
3. Increases insulin secretion in response to meals, helping regulate blood sugar.
4. Works both on weight loss and metabolic improvements (e.g. lipids, blood pressure) as shown in clinical trials.

Indications / Who Can Use Zepbound (Tirzepatide)

Zepbound is FDA-approved for:

Adults with obesity (BMI ≥ 30 kg/m²), or
Adults with overweight (BMI ≥ 27 kg/m²) who have weight-related medical conditions (e.g. type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea) .
Also specifically approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

It should not be used in children, with other tirzepatide products, or with other GLP-1 receptor agonists.

Dosage and Administration

Stage	Dose	Frequency	Notes
Initiation	2.5 mg once weekly	Subcutaneous injection	First 4 weeks, to improve tolerability.
Titration	Increase in 2.5 mg increments every ≥ 4 weeks	Weekly	Up to maintenance dose.
Maintenance	5 mg, 10 mg, or 15 mg once weekly	Weekly	Best results (weight loss) seen at higher maintenance doses in studies.

Available in single-use pens and single-dose vials.
Injection sites: abdomen, thigh, or upper arm. Rotate injection site to avoid irritation.
Use of Zepbound must be paired with a reduced-calorie diet and increased physical activity.

Clinical Trial / Efficacy Data

In a 72-week trial of adults without diabetes, average weight loss was approx 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg doses, compared to ~3.1% for placebo.
Similar substantial weight loss observed in people with type 2 diabetes.
In people with OSA, significant improvement in sleep apnea severity was seen, with many shifting to mild or no OSA after treatment.